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Abstract
Immunity to one of the four dengue virus (DV) serotypes can increase disease severity in humans upon subsequent
infection with another DV serotype. Serotype cross-reactive antibodies facilitate DV infection of myeloid cells in vitro by
promoting virus entry via Fcc receptors (FccR), a process known as antibody-dependent enhancement (ADE). However,
despite decades of investigation, no in vivo model for antibody enhancement of dengue disease severity has been
described. Analogous to human infants who receive anti-DV antibodies by transplacental transfer and develop severe
dengue disease during primary infection, we show here that passive administration of anti-DV antibodies is sufficient to
enhance DV infection and disease in mice using both mouse-adapted and clinical DV isolates. Antibody-enhanced lethal
disease featured many of the hallmarks of severe dengue disease in humans, including thrombocytopenia, vascular leakage,
elevated serum cytokine levels, and increased systemic viral burden in serum and tissue phagocytes. Passive transfer of a
high dose of serotype-specific antibodies eliminated viremia, but lower doses of these antibodies or cross-reactive
polyclonal or monoclonal antibodies all enhanced disease in vivo even when antibody levels were neutralizing in vitro.I n
contrast, a genetically engineered antibody variant (E60-N297Q) that cannot bind FccR exhibited prophylactic and
therapeutic efficacy against ADE-induced lethal challenge. These observations provide insight into the pathogenesis of
antibody-enhanced dengue disease and identify a novel strategy for the design of therapeutic antibodies against dengue.
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Introduction
The four serotypes of dengue virus (DV) are mosquito-borne
flaviviruses responsible for 50–100 million human infections
annually. Primary infection in individuals over the age of one
year with any DV serotype is usually asymptomatic or results in
self-limited dengue fever (DF), but secondary infection with
another DV serotype carries an increased risk of severe disease,
including life-threatening dengue hemorrhagic fever/dengue
shock syndrome (DHF/DSS) [1,2]. Fatal disease is characterized
by increased vascular permeability leading to hemoconcentration
and hypovolemic shock [3]. The increased severity of secondary
infections is believed to result, at least in part, from antibody-
dependent enhancement (ADE) of DV infection, in which FccR
engagement by antibody-virus immune complexes facilitates virus
entry into susceptible myeloid cell types [4]. A role for ADE in
human dengue pathogenesis is supported by observations that
maternally-derived anti-DV antibodies increase the risk of DHF in
infants during primary infection with DENV2 [5,6]. Antibody-
mediated increases in DV viremia have been demonstrated in
macaques, but a limited number of antibody conditions were
examined, and exacerbation of dengue disease by passively
transferred antibodies was not observed [7,8]. Consequently,
fundamental questions about the immunology and pathogenesis of
ADE have remained unanswered, and small animal models for
testing antiviral interventions in the context of ADE have not been
available.
Recently, we derived a mouse-adapted DV2 strain, D2S10, that
produces a TNF-a-dependent fatal vascular permeability syn-
drome in interferon-a/b and c-receptor-deficient (AG129) mice
4–5 days after intravenous (iv) infection with 10
7 plaque forming
units (pfu) of virus [9]. DV infection in AG129 mice reproduces
important features of human DV infection, including similar tissue
and cellular tropism, viremia, vascular leakage, and elevated
serum cytokine levels [9–12]. Antibodies elicited by DV infection
are a mixture of serotype-specific and serotype-cross-reactive
antibodies, including long-lasting neutralizing antibodies [13].
Memory immune responses are present after primary DV
infection, and serotype cross-protective immunity was observed
in three different sequential infection scenarios ([13] and data not
PLoS Pathogens | www.plospathogens.org 1 February 2010 | Volume 6 | Issue 2 | e1000790shown). Thus, we utilized the AG129 model to examine the effects
of serotype cross-reactive antibodies on DV2 infection in vivo.I n
this report, we demonstrate lethal enhancement of DV infection
and disease by both polyclonal and monoclonal antibodies. We
also show that ADE functions to increase the viral burden in blood
and tissues, resulting in a vascular permeability syndrome that is
similar to that seen in mice with a higher inoculum in the absence
of immune antibody and that shares clinical features of human
dengue disease. Finally, we confirm the critical role of FccR
interaction in ADE in vivo and provide proof-of-principle for a pre-
and post-exposure treatment strategy utilizing genetically engi-
neered monoclonal antibodies that can no longer bind FccR.
Results
Lethal enhancement of dengue disease by anti-DV serum
Serum containing anti-DV1 antibodies was collected from
AG129 mice 8 weeks after subcutaneous inoculation with 10
5 pfu
of DV1 strain 98J. Heat-inactivated anti-DV1 serum exhibited a
50% neutralizing titer (NT50) against DV2 strain D2S10 of 1:296
and against DV1 98J of 1:1,069 using a flow-based neutralization
assay [14], peak enhancement titers of 1:75 against DV2 D2S10
(fold-enhancement 14.8%) and 1:225 against DV1 98J (fold-
enhancement 10.7%) in an in vitro ADE assay with FccR-bearing
human K562 cells, and ELISA titers of 400 and 3200 against
purified DV2 and DV1, respectively (data not shown). In addition,
no residual DV1 could be isolated following inoculation into C6/36
mosquito cells (data not shown). The effects of anti-DV1 serum on
DV2 infection were investigated after intraperitoneal (ip) injection
of 100 ml of either naı ¨ve mouse serum (NMS) or anti-DV1 serum,
followed 24 hours later by iv challenge with 10
4–10
6 pfu of DV2.
Lethalinfectioncontrolsreceived10
7 pfuofDV2,andallmicewere
monitored for mortality for 10 days. While no mortality was
observed in NMS-recipient mice infected with 10
6 pfu or less of
DV2, 92–100% of anti-DV1 recipients died after inoculation with
10
5–10
6 pfu of DV2 (Figure 1A and Table S1) between 4 and 5
days post-infection. In both the 10
7 pfu infection controls and anti-
DV1 recipients infected with 10
5 or 10
6 pfu, lethal disease was
accompanied by fluid accumulation in visceral organs characteristic
of the vascular permeability syndrome induced by DV2 D2S10 [9]
(Figure 1B). Mice administered anti-DV1 serum and challenged
with DV2 D2S10 also experienced significant increases in serum
TNF-a (p,0.01) and IL-10 (p,0.01) and greater platelet depletion
(p,0.02), as compared to NMS-recipient controls (Figure 1C–F);
eachof these disease parametersalso correlateswithdengueseverity
in humans [15–17].
Anti-DV antibody increases systemic viral burden
Viral burden was subsequently compared between anti-DV1 and
NMS-recipient mice infected with 10
5 or 10
6 pfu of DV2. Viral
burden was systemically increased in anti-DV1 versus NMS-
recipient mice, with a 20-fold increase (p,0.02) in viremia
accompanied by significant 3- to 12-fold increases in viral load in
multiple tissues (p#0.04) including peripheral blood mononuclear
cells, liver, small intestine, lymph node, and bone marrow
(Figure 2A); non-significant increases in the large intestine and
spleen (p.0.08) and lungs (data not shown) were observed. No
statistically significant differences were observed in tested disease
parameters, viral burden, or tissue tropism between 10
7 pfu of
D2S10 infection in the absence of antibody and antibody-enhanced
infection with 10
5 pfu of D2S10. Notably, anti-DV antibodies also
enhanced infection with non-adapted low-passage human DV
isolates DV1 Western Pacific-74 (Figure 2B) and DV2 TSV01
(Figure2C),asdeterminedbysignificantincreases(p#0.04)inviral
burden in the liver and small intestine for both viruses, and in serum
for DV2 TSV01. Although mortality was not observed, a subset of
animals infected with DV1 Western Pacific-74 under antibody-
enhanced conditions displayed fluid accumulation in visceral organs
and gross morphology similar to but less pronounced than that
observed with enhanced DV2 D2S10 disease.
Increased infection of FccR-bearing cells during ADE
ADE is predicted to facilitate infection of FccR-bearing cell types
such as tissue macrophages and dendritic cells [4]; therefore, we
examined the cellular tropism of DV2 in mice by immunostaining
for the viral NS3 protein, which is only present during active
replication of the virus. As found in humans [12,18], infected cells
with morphology and location consistent with tissue macrophages
or dendritic cells [19,20] were detected in lymph node, small
intestine, large intestine, and bone marrow under all infection
conditions, and NS3
+ cells with endothelial and/or phagocyte
morphology were also observed in liver (Figure 3 and data not
shown). Infection in myeloid cells was confirmed by co-staining of
serial sections and bone marrow aspirates for NS3 and the myeloid/
macrophage marker F4/80 (data not shown). Furthermore, using
flow cytometry, DV NS3 and E protein were detected in bone
marrow cells expressing myeloid markers CD11b, CD11c, and F4/
80, and in liver DV infection was primarily in CD31
+CD45
2
sinusoidal endothelial cells, which also express FccR( Figure S1).
Notably, significantly greater numbers of NS3
+ cells (p#0.05) were
present in tissues of anti-DV1 recipient mice compared to naı ¨ve
serum recipient controls infected with the same dose of DV2
(Figure 3B), supporting the hypothesis that ADE functions to
increase the viral burden in cells and tissues.
Effect of antibody dose on ADE in vivo
While serotype cross-reactive immunity is implicated in the
pathogenesis of severe dengue, serotype-specific immunity typi-
cally protects against re-infection with the same DV serotype [1].
Author Summary
Dengue is the most common vector-borne viral disease of
humans, with over 3 billion people at risk for infection and
50–100 million infections in tropical and subtropical
regions each year. Dengue virus (DV) causes a spectrum
of clinical disease ranging from an acute debilitating, self-
limited febrile illness (DF) to a life-threatening vascular
leakage syndrome, referred to as dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS). There are four
serotypes of DENV; infection with one serotype is thought
to protect against re-infection with the same serotype, but
may either protect against or enhance infection with one
of the other three serotypes. Epidemiological and in vitro
data has implicated anti-DENV antibodies in mediating
pathogenesis of a second DENV infection. However, it is
unclear which antibody conditions are protective and
which exacerbate disease in vivo, in part because no
animal model of antibody-enhanced dengue disease has
been available. Here, we present the first animal model of
antibody-enhanced severe DENV infection. Importantly,
this model recapitulates many aspects of human disease,
including vascular leakage, elevated serum cytokine levels,
reduced platelet count, and disseminated infection of
tissue phagocytes. Furthermore, we demonstrate the
utility of this model by showing that a genetically modified
anti-DENV antibody that fails to bind the Fcc receptor has
prophylactic and therapeutic efficacy against lethal DENV
challenge in vivo.
Mouse Model for Antibody-Enhanced Dengue Disease
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infection are capable of ADE at some lower concentration [21];
therefore, we examined the effects of anti-DV1 and anti-DV2 sera
on DV2 D2S10 infection in mice over a range of doses. While the
highest dose (400 ml) of anti-DV1 serum lethally enhanced
infection (Figure 4A and Table S2), recipients of 400 mlo f
anti-DV2 serum developed no signs of illness and lacked
detectable viremia (Figure 4B and C; Table S2), confirming
that serotype-specific antibodies can provide robust protection in
this model. However, lower doses of both anti-DV1 and anti-DV2
serum caused lethal enhancement, showing that serotype-specific
as well as serotype-cross-reactive antibodies can also enhance
infection in vivo in a dose-dependent manner (Figure 4A and B).
To assess the ability of the BHK PRNT50 assay to predict in vivo
protection and enhancement in this mouse model, neutralizing
activity was measured in the sera of mice immediately prior to
infection with D2S10. Serum was collected approximately
18 hours post-transfer of anti-DV antibodies, and 4 hours prior
to infection. Similar to human studies [22], lethal enhancement
occurred even in mice that had detectable neutralizing antibodies,
although no lethality was observed in mice with PRNT50 values of
.200.
Figure 1. Lethal enhancement of dengue disease by anti-DV sera. A. Mice were administered 100 ml naı ¨ve mouse serum (NMS) or anti-DV1
serum (a-DV1), challenged iv with the indicated dose of DV2 strain D2S10 24 hours later, and monitored for survival. Kaplan-Meier survival curves are
shown; see Table S1 for p-values. The numbers of mice per group are as follows: NMS +10
7 D2S10, 15; NMS +10
6 D2S10, 8; NMS +10
5 D2S10, 11; NMS
+10
4D2S10,4;a98J +10
6 D2S10,12;a98J+10
5 D2S10, 4;a98J+10
4 D2S10,4.B–F.Diseaseparameterswerecomparedinmicereceivingnovirus,10
7 pfu
DV2, or 10
5 pfu DV2 after transfer of naı ¨ve or anti-DV1 serum. B. Vascular leak-associated fluid accumulation in visceral organs at day 3.5 post-infection.
C–E.SerumlevelsofTNF-a (C),IL-10(D),andIL-6 (E) ininfectedmiceatday3.5post-infectionweremeasuredbyELISA(eBioscience).F.Plateletcountsin
mice at day 3.5 post-infection were determined using a hemocytometer. In (C–F), n=4 in all groups except the uninfected group in panel F, where
n=12. Error bars represent standard deviations, and two-sided Wilcoxon rank sum tests were used to determine statistical significance.
doi:10.1371/journal.ppat.1000790.g001
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examined the ability of monoclonal antibodies (mAbs) to enhance
DV disease in mice. Mice were inoculated with DV2 D2S10
24 hours after transfer of increasing amounts of the flavivirus
cross-reactive, neutralizing mAb 4G2 (Figure 4D). 4G2 caused
lethal enhancement at doses of 0.062–4 mg/kg (1.25–80 mg/
mouse), but no mortality occurred in mice receiving 20mg/kg
(400 mg/mouse) or in IgG2a isotype control antibody recipients
Figure 2. Enhancement by heterologous anti-DV antibodies increases systemic viral burden of mouse-adapted and clinical isolates
of DV. A. Mice were administered 100 ml NMS or anti-DV1 serum ip and infected 24 hours later with 10
5 pfu DV2 D2S10 iv; lethal infection controls
were infected iv with 10
7 pfu DV2 D2S10. Viral burden was measured in the indicated tissues at day 3.5 post-infection by qRT-PCR (serum) or plaque
assay (all other tissues) as described in Materials and Methods. B. Mice were administered 100 ml NMS or anti-DV2 serum ip and infected the next day
with 3610
6 pfu DV1 Western Pacific-74 iv. Virus burden was measured in the indicated tissues at day 3.5 post-infection by qRT-PCR (serum) or plaque
assay (all other tissues) as described in the Materials and Methods C. Mice were administered 20 mg anti-DV MAb 4G2 or PBS ip and infected the next
day with 10
6 pfu DV2 TSV01 iv. Virus burden was measured as in (A). Symbols indicate values in individual mice. Limits of detection are represented
by dashed lines when present, or the horizontal axes. All pairwise comparisons were performed by two-sided Wilcoxon Rank Sum tests.
doi:10.1371/journal.ppat.1000790.g002
Mouse Model for Antibody-Enhanced Dengue Disease
PLoS Pathogens | www.plospathogens.org 4 February 2010 | Volume 6 | Issue 2 | e1000790Figure 3. Detection and quantification of DV-infected cells with or without antibody-dependent enhancement. Mice were
administered naı ¨ve serum (NMS) or anti-DV1 serum and infected iv with 10
5 pfu DV2 the following day. Controls were mock-infected or infected with
10
7 pfu DV2 iv. A. Tissues were collected from all mice (n=3–6 per group) at day 3.5, formalin-fixed, and processed into paraffin sections. Serial
sections from each tissue were stained with anti-DV NS3 antibody E1D8 (NS3) or an isotype control mouse IgG2a (IgG2a data not shown), and
multiple sections of each tissue type were thoroughly examined for staining. Positive staining for NS3 is brown while hematoxylin counterstain is
blue. Strong cytoplasmic staining observed with E1D8, but not IgG2a control antibody, was considered DV-specific when observed in infected mice
but not uninfected controls. NS3
+ cells in lymph node, small intestine, and large intestine exhibited morphology and location consistent with tissue
macrophages under all infection conditions (arrowheads). In liver, NS3
+ cells were consistent with tissue macrophages and/or endothelial cells. Serial
sections showed the F4/80 macrophage marker staining in the same locations where infected cells were present in lymph nodes, small intestine,
large intestine, and bone marrow (data not shown). B. NS3
+ cells per visual field were quantified. At least ten visual fields were counted for each
sample except bone marrow, where four fields from four independent sections were counted due to the small area of mouse bone cross-sections. All
pairwise comparisons were performed by two-sided Wilcoxon Rank Sum tests.
doi:10.1371/journal.ppat.1000790.g003
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PLoS Pathogens | www.plospathogens.org 5 February 2010 | Volume 6 | Issue 2 | e1000790(Figure 4D and Table S2). 4G2, anti-DV1 serum, and anti-DV2
serum all enhanced infection and disease over a ,60-fold range in
concentration.
ADE requires FccR interaction in vitro and in vivo
Since FccR engagement is required for ADE in vitro [23], we
hypothesized that eliminating the ability of antibodies to bind to
FccRs would prevent ADE in vivo. To test this, we first generated
F(ab9)2 fragments of 4G2. These fragments were indistinguishable
from intact 4G2 in their ability to bind to DV2 E protein by
ELISA (Figure S2A), but were unable to enhance DV infection of
the human FccR-bearing cell line K562 (Figure 5A). The lack of
the Fc portion in the F(ab9)2 fragments of 4G2 was confirmed by
ELISA (Figure S2B). In vivo, F(ab9)2 fragments have a shorter
serum half-life than intact IgG, thus it was necessary to identify a
dosing regimen that would maintain serum concentration of
F(ab9)2 fragments within the known enhancing range for intact
IgG antibodies. Serum F(ab9)2 levels were measured one and
24 hours after iv transfer of 20 mg of F(ab9)2 by E protein ELISA;
this dose maintains E-reactive antibodies at levels within the range
where IgG causes enhancement for 24 hours (Figure S2C). To
examine the effects of intact IgG and F(ab9)2 in vivo, we compared
the enhancing effects of a single dose of 4G2 mAb with daily 20 mg
doses of 4G2 F(ab9)2 (Figure 5B). Whereas significant mortality
was observed in 4G2 mAb recipients (p#0.04), no illness occurred
in 4G2 F(ab9)2 or IgG2a isotype control recipients (Figure 5C).
Viremia measured at 3.5 days post-infection in F(ab9)2 recipients
was significantly reduced (p,0.03) compared to isotype control
antibody recipients (Figure 5D), suggesting that loss of FccR
interaction not only diminished enhancement but also promoted
neutralization to reduce viral load.
We followed up these studies using a mAb genetically
engineered to eliminate FccR binding. MAb E60 is a flavivirus
cross-reactive neutralizing mouse IgG2a antibody that, similar to
4G2, binds to an epitope in the fusion peptide of domain II on the
E protein [24,25]. This mAb was cloned and the constant regions
replaced [26] with those from human IgG1 to create an E60-
chimeric human IgG1 (E60-hIgG1). In addition, an asparagine to
glutamine variant at position 297 in human IgG1 was engineered
(E60-N297Q), as this mutation abolishes FccR binding without
altering the half-life of the antibody in mouse serum [27]. Affinity
measurements conducted by surface plasmon resonance indicated
that E60-mouse IgG2a (E60-mIgG2a), E60-hIgG1, and E60-
N297Q all exhibited similar binding to purified E protein (Figure
S3A) and DV2-infected cells by flow cytometry (data not shown),
as well as similar neutralizing activity against DV2 by both
PRNT50 assay (0.23, 0.25, and 0.42 mg/ml, respectively) and a
neutralization assay using DC-SIGN-expressing human target cells
(Figure S3B). However, as expected, E60-mIgG2a and E60-
hIgG1 enhanced DV2 infection of K562 cells in vitro whereas E60-
N297Q did not (Figure 6A).
To test the ability of the E60-N297Q variant to enhance DV
infection in vivo, mice were administered 20 mg of E60-mIgG2a,
E60-hIgG1, and E60-N297Q 24 hours prior to infection with
10
6 pfu of D2S10. Whereas both E60-mIgG2a and E60-hIgG1
consistently caused antibody-dependent mortality 4 to 5 days post-
infection, equivalent doses of E60-N297Q caused neither
morbidity nor mortality (Figure 6B). Instead, viremia and tissue
viral burden in E60-N297Q recipients were substantially reduced,
demonstrating that the N297Q mutation converted the in vivo
effect of E60 on viral burden from enhancement to neutralization
(Figure 6C, and data not shown).
The N297Q mutation also abolishes binding to complement
component C1q [27]. Consequently, we generated a second
variant antibody, E60-A330L, to assess whether the loss of C1q
binding or the loss of FccR binding explained the inability of E60-
N297Q to mediate ADE. E60-A330L does not bind C1q but
retains binding to FccR [28], and we confirmed this by surface
plasmon resonance (data not shown). E60-A330L exhibited similar
binding and neutralization activity to E60-hIgG1, enhanced DV
infection in vitro in K562 cells, and lethally enhanced a DV2-
D2S10 infection in vivo (Figure S3B, C, and D, and data not
Figure 4. Antibody conditions for enhancement of DV
infection. A. Mice were administered 1.6–400 ml anti-DV1 serum ip,
and pre-infection serum samples were collected the next day. Mice
were then infected with 10
5 pfu DV2 iv and monitored for survival.
Neutralizing activity of each pre-infection serum was determined in
duplicate by PRNT50 assay on BHK21-15 cells. For each serum dose,
PRNT50 results are displayed as the average of 3 to 4 mice, with the
range in brackets. B. Serum transfers, bleeds, virus challenges, and
PRNT assays were performed as in (A), but using anti-DV2 serum
generated in AG129 mice. C. Viremia was measured in naı ¨ve serum
controls (n=4) and recipients of 400 ml anti-DV2 serum (n=3) on day 4
post-infection by qRT-PCR. D. Mice were administered 1.25–400 mgo f
anti-DV monoclonal antibody 4G2, and pre-infection bleeds, challenges,
and PRNT assays were performed as in (A).
doi:10.1371/journal.ppat.1000790.g004
Mouse Model for Antibody-Enhanced Dengue Disease
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in vivo, and a loss of C1q binding does not explain the inability of
E60-N297Q to enhance DV infection.
An antibody that cannot bind FccR has both prophylactic
and therapeutic potential
The experiments above suggested that an N297Q variant
antibody against DV could have potential as an antiviral
intervention. To assess this, 20 mg of E60-hIgG1 or E60-N297Q
was administered concurrently with 25 ml of anti-DV1 serum 1
day prior to infection with DV2. E60-N297Q protected mice
against any signs of illness, whereas all recipients of anti-DV1/
E60-hIgG1 succumbed to infection (Figure 7A). Post-exposure
therapeutic application of E60-N297Q was evaluated by admin-
istering 25 ml anti-DV1 serum to mice, followed by infection with
DV2 the next day, and iv administration of E60-N297Q or E60-
hIgG1 on day 1 or 2 post-infection. While all mice treated with
E60-hIgG1 succumbed to infection, lethality was completely
prevented by a single 20 mg dose of E60-N297Q on day 1
(Figure 7B and data not shown), and E60-N297Q treatment
significantly decreased viremia, tissue viral burden, and serum
TNF-a levels as measured 3.5 days post-infection (Figure 7C and
7D, p,0.04). Moreover, 20 or 50 mg doses of E60-N297Q
administered on day 2 resulted in 40% and 80% survival,
respectively, demonstrating therapeutic efficacy for this antibody
in mice (Figure 7B).
Discussion
Understanding the immunopathogenesis of DV infection has
been severely hampered by the lack of a small animal disease
model. Thus, studies of ADE have been limited to epidemiological
observations and in vitro experimentation. Here, we present the
first model of antibody-enhanced lethal dengue disease in vivo. This
work describes a long-sought mouse model for investigation of
dengue pathogenesis, characterizes a clinically important mecha-
nism of immunopathogenesis, has implications for vaccine
development, and identifies a possible antibody-based antiviral
strategy to treat life-threatening DV infection.
Numerous attempts have been made to establish a mouse model
of dengue disease and have been limited by the relatively low
Figure 5. Antibodies that lack the Fc region fail to mediate ADE and instead protect against lethal challenge. A. Infection of K562 cells
by DV2 in the presence of 4G2 mAb or 4G2 F(ab9)2 fragment was determined 48 hours post-infection by staining with Alexa488 anti-DV E protein
MAb followed by flow cytometry. Average infection without antibody was 0.74%. B. Dosing scheme used to compare the in vivo effects of F(ab9)2
and intact mAb. Mice were administered intact 4G2 or IgG2a control mAb on day 21, or 20 mg doses of F(ab9)2 every 24 hours beginning 1 hour
prior to infection, and were then challenged with 10
5 pfu of DV2 iv. C. Survival in mice from (B) receiving the indicated antibodies was scored on day
4 post-infection, and a two-sided Fisher’s exact test was used. D. Viremia at day 4 post-infection in surviving mice from (C), measured by qRT-PCR.
Error bars represent standard deviations, and pairwise comparisons were performed by two-sided Wilcoxon rank sum tests.
doi:10.1371/journal.ppat.1000790.g005
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included intracerebral inoculation of DV or injection of very high
(.10
9 PFU) doses of virus into immunocompetent mice [29,30];
infection of SCID [31–34] or NOD/SCID or RAG2c (c)
2/2mice
[35,36] implanted with human cells or cell lines; and use of various
immunodeficient strains of mice [37,38]. The most common
outcome is neurovirulent disease, with a few recent exceptions
[35,36]. Of these, the AG129 mouse model has proven both useful
and tractable, as it is permissive to infection with all four DV
serotypes, displays relevant tissue and cellular tropism, produces
long-lasting serotype-specific and serotype-cross-reactive anti-DV
antibodies of a balanced isotype ratio, and generates a vascular
leakage syndrome that in many respects resembles human dengue
disease [9–11,13,12]. Nonetheless, we acknowledge that the lack of
IFN receptors limits reproduction of some facets of human disease,
especially in relation to cytokine profiles or infection conditions
that are modulated by IFNs. However, the many similarities with
specific features of human DV infection and the critical role for
FccR in ADE in vivo that we demonstrate here support the use of
the AG129 model for specific avenues of dengue research.
Interestingly, IFN-receptor deficient mice (A129) have recently
been successfully adapted for other mosquito-borne viruses,
including both Chikungunya and Yellow Fever [39,40].
In vivo ADE models have also been established for other viruses,
including Yellow Fever Virus (YFV), Murray Valley Encephalitis
Virus (MVEV), Japanese Encephalitis Virus (JEV), and Feline
Infectious Peritonitis Virus (FIPV) [41–46], in which passive
transfer of antibody increases viral titers and/or mortality. These
models show several parallels with our model of antibody-
enhanced DENV infection: with FIPV, immune sera are able to
enhance macrophage infection and disease during subsequent
challenge with the same FIPV serotype in kittens [41,46], and with
MVEV, JEV, and YFV, enhanced mortality was observed in mice
administered flavivirus cross-reactive polyclonal antibodies or non-
neutralizing YFV-specific monoclonal antibodies [42–45]. How-
ever, none of these pathogens are associated with antibody-
enhanced disease in humans. By modelling ADE with a pathogen
known to cause antibody-enhanced disease in humans and using a
model that displays a variety of relevant disease phenotypes, this
report extends previous work on ADE to the ability to model
human disease parameters and aid in the development of
therapeutics.
In vivo evidence of ADE of DV infection was first described by
Halstead et al [7] following the passive transfer of antibodies in the
rhesus macaque. Similar data was recently obtained by Gonc ¸alvez
et al [8], where passive transfer of the serotype-cross-reactive mAb
1A5 enhanced DV4 viremia over a ,30-fold concentration range
(0.22–6 mg/kg). While both of these studies described elevated
viremia, neither resulted in a clinical phenotype with parallels to
human disease. Here, we describe enhancement of a mouse-
adapted strain of DV2 by serotype-specific and cross-reactive sera
as well as by monoclonal antibodies. Importantly, characterization
of antibody-dependent dengue disease in the AG129 mouse
maintains several parallels with severe disease in humans.
Hallmark features of human DHF/DSS are vascular leak, higher
viral burden, increased levels of serum cytokines such as TNF-a
and IL-10, and platelet depletion [47]. All of these features were
observed in our mouse model of ADE. Moreover, the magnitude
of DV enhancement also mimics that seen in humans and non-
human primates. We observed a 20-fold increase in viremia
triggered by ADE; DV viremia in humans is reported to be 10- to
100-fold higher in DHF cases than in DF cases [48,49], and ADE
in macaques increases viremia 5–100 fold [7,8]. Interestingly, in all
of the disease parameters we examined, there was no apparent
difference between lethality resulting from antibody-enhanced
infection with a sublethal viral dose and lethality resulting from
direct inoculation with a 100-fold higher viral dose. Thus, this
model did not reveal any fundamental difference in the
mechanisms of pathogenesis between antibody-enhanced and
non-enhanced infection; rather, lethality here appears to be a
result of higher viral burden, regardless of how such a burden was
achieved.
To ensure that enhanced disease in the AG129 model was not
solely a feature of the mouse-adapted strain, mice were infected
with clinical isolates DV1 Western Pacific-74 and DV2 TSV01 in
the presence of anti-DV antibodies, and enhanced viremia was
observed in both cases. The lack of mortality in infections with
these viruses is likely a result of the lower viral burden established
by non-adapted strains even in the presence of enhancing
Figure 6. Antibodies with a mutated FccR binding site cannot
enhance DV infection in vitro or in vivo.A .Infection of K562 cells
by DV2 in the presence of E60-mIgG2a, E60-hIgG1, E60-N297Q. B. Mice
were administered 20 mg of the indicated E60 mAbs, challenged
24 hours later with 10
6 pfu DV2 iv, and monitored for survival (n=4
mice per group). p=0.02 for E60-hIgG1 versus E60-N297Q. C. Mice were
administered E60 mAbs and virus as in (B), and viral burden in
peripheral blood cells was measured by plaque assay. n=4 mice per
group.
doi:10.1371/journal.ppat.1000790.g006
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in the gastrointestinal organs in a subset of mice experiencing
enhanced infection of non-adapted DV. As only a small fraction
(0.5%) of human secondary DV infections results in severe disease,
and some DV strains are more virulent than others based on
genetic differences [50], the observed spectrum in disease severity
is not surprising, but rather parallels the human condition.
Immunohistochemical (IHC) characterization of the cellular
tropism associated with ADE using NS3-specific antibodies
indicated infection in cells with morphology consistent with
dendritic cells and tissue macrophages in the lymph node, small
intestine, large intestine and bone marrow. Further characteriza-
tion by flow cytometry supported the IHC data and demonstrated
infection, as evidenced by both anti-E and anti-NS3 staining, in
cells with surface markers of monocytes and macrophages in the
bone marrow and sinusoidal endothelial cells in the liver. By both
methodologies, the infected cell types identified in the murine
model agree with those cells defined as the natural targets of DV in
the human host [12,18]. Interestingly, the infected cell types did
not change between an enhanced and non-enhanced DV
infection; rather, quantification by both IHC and flow cytometry
indicated an increase in the number of infected cells. Taken
together, antibody-enhanced disease appears to result in increased
infection in the natural targets of DV infection and resulting
pathogenesis that does not significantly differ from the disease that
results when a 100-fold higher dose of DV is used in the absence of
enhancing antibody.
In human infants who have acquired maternal anti-DV
antibody, severe dengue can occur even when calculated
neutralizing antibody titers against the secondary infecting
serotype are .1:100 [51]. Similarly, children with detectable
neutralizing antibody against the infecting virus strain can develop
DHF during secondary DV infections [22]. These studies indicate
that the in vitro neutralization assay using BHK21 cells is not a
consistent correlate of protection in humans. Similarly, our
PRNT50 assays performed on serum samples from mice after
antibody transfer but before virus challenge demonstrated that
despite in vitro neutralizing activity at the time of infection, anti-
DV1 sera, anti-DV2 sera, and 4G2 all enhanced infection in vivo.
Enhanced disease was consistently observed in antibody-recipient
mice with pre-infection neutralizing titers of ,1:200, but not
greater. Thus, substantial neutralizing antibody levels appear to be
required to prevent severe disease in this model. Of note, the
passive transfer and primary infection scheme used does not
examine anamnestic B and T cell immune responses, and thus,
more accurately models DHF/DSS in infants with primary DV
infection rather than secondary DV infections.
In vitro evidence had previously indicated that an interaction
between the Fc portion of the antibody and the FccR was
necessary for ADE [8]; however, this hypothesis had never been
corroborated in vivo. Using two different reagents – F(ab)92
fragments of 4G2 and the N297Q variant of hE60-IgG1, we
demonstrate that binding of the Fc portion of the antibody to the
FccR is required for ADE-induced disease. Further analysis with
F(ab)92 or the N297Q variant showed a reduction in viral titer
below the level in mice receiving PBS in place of mAb. Thus,
Figure 7. Antibodies with a mutated FccR binding site have
both prophylactic and therapeutic potential and reduce viral
load and serum TNF-a in DV-infected mice. A. Mice were
simultaneously administered 25 ml anti-DV1 serum and 20 mg of the
indicated E60 mAbs ip, challenged 24 hours later with 2610
5 pfu of
DV2 iv, and monitored for survival (n=5 mice per group). p=0.009 for
E60-hIgG1 versus E60-N297Q recipients. B. Mice were administered
25 ml anti-DV1 serum ip, challenged 24 hours later with 10
5 pfu of DV2
iv, treated by iv administration of E60-N297Q at the indicated doses and
days post-infection, and monitored for survival. p-values compared to
untreated controls (n=9) were: p=0.008 for 20 mg E60-N297Q on day 1
post-infection (n=5); p=0.005 for 20 mg E60-N297Q on day 2 post-
infection (n=10); and p=0.02 for 50 mg E60-N297Q on day 2 post-
infection (n=5). Survival differences were compared using logrank
tests. C. Mice were administered 25 ml of anti-DV1 serum ip and
infected iv the next day with 10
5 pfu of DV2. Mice were injected iv with
either PBS (untreated) or 20 mg E60-N297Q 24 hours later. On day 3.5
p.i, mice were euthanized and serum and tissues were collected. Viral
burden in serum, small intestine, and bone marrow were measured by
qRT-PCR for serum and plaque assay for solid tissues. D. Serum TNF-a
was measured by ELISA. n=4 mice per group in all analyses. For viral
load and TNF-a values, error bars represent standard deviations, and
pairwise comparisons were performed by two-sided Wilcoxon rank sum
tests.
doi:10.1371/journal.ppat.1000790.g007
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F(ab) portion of the antibody can neutralize infection. These data
also demonstrate that antibodies directed to the fusion loop in E
domain II are capable of neutralizing DV infection independently
from effector functions mediated by FccR and C1q. Because the
N297Q mutation also ablated the C1q binding site, we tested a
second hE60 variant, hE60-A330L, that contained a mutation
disrupting the complement C1q receptor binding site, but not the
FccR interaction. Mice receiving the hE60-A330L variant
succumbed to an enhanced DV infection. This confirms that
interaction of the anti-DENV mAb with the FccR, and not
binding of C1q, is essential for ADE in vivo.
Given the promising data with the hE60-N297Q variant, we
tested the prophylactic and therapeutic efficacy of this antibody.
When given as prophylaxis together with an enhancing amount of
anti-DV1 serum, hE60-N297Q was completely protective. Al-
though interesting, a DENV prophylactic is not likely to be a
clinically useful reagent. However, when given 24 hours after an
enhanced DENV infection, E60-N297Q completely protected
against mortality; likewise, tissue viral load and systemic TNF-a
levels in these mice at 3.5 days post-infection were significantly
reduced. Two different doses of E60-N297Q, 20 and 50 mg, were
administered 48 hours post-infection and resulted in 50% and
80% survival, respectively. Given the condensed timeframe of
DENV pathogenesis in the AG129 model, E60-N297Q or similar
therapeutic mAbs may have a broader time window for
intervention and efficacy in humans or other animal models that
display more protracted kinetics of DV infection.
In summary, we report the first animal model of lethal
antibody-mediated enhancement of DV infection, describe
virologic and pathologic changes induced by ADE, and define
antibody conditions for protection and ADE in passive antibody
transfer recipients. Furthermore, we show that antibodies
engineered to prevent FccR interaction exhibit prophylactic and
therapeutic efficacy against DV infection, and thus have potential
as a novel antiviral strategy against DV.
Materials and Methods
Ethics statement
All experimental procedures were pre-approved by the UC
Berkeley Animal Care and Use Committee and were performed
according to the guidelines of the UC Berkeley Animal Care and
Use Committee.
Viruses, cell lines and monoclonal antibodies
DV was propagated in the Aedes albopictus cell line C6/36
(American Type Culture Collection [ATCC]) as described
elsewhere [52]. DV2 strain D2S10 (passaged 4 times in C6/36
cells) was derived in our laboratory [9] from the parental DV2
PL046 Taiwanese isolate as previously described [9]. The DV1
strain 98J was isolated in our laboratory from a patient from
Guyana in 1998 [53] and passaged 7 times in C6/36 cells. The
DV1 strain Western Pacific 74, originally isolated in Nauru in
1974, was obtained from the National Institutes for Biological
Standards and Control (Hertfordshire, UK) and passaged 3 times
in C6/36 cells. The DV2 strain TSV01, isolated in Townsville,
Australia, in 1993 was obtained from W. Schul, passaged ,10
times in C6/36 cells (Novartis Institute for Tropical Diseases,
Singapore) [11]. Virus titers were obtained by plaque assay on
baby hamster kidney cells (BHK21, clone 15) as described [52].
For mouse experiments, virus was concentrated by centrifugation
at 53,0006g for 2 hours at 4uC and resuspended in cold PBS with
20% FBS (HyClone, Thermo Scientific). U937 DC-SIGN cells
were obtained from A. de Silva (University of North Carolina,
Chapel Hill) and grown in RPMI media (Invitrogen) at 37uCi n
5% CO2. K562 cells were used for all enhancement assays and
grown in RPMI media (Invitrogen) at 37uCi n5 %C O 2. The
hybridoma of mAb 4G2 was purchased from ATCC, grown in
serum-free medium (Invitrogen), and purified using protein G
affinity chromatography (Thermo Scientific). Mouse mAb E60
and human E60-IgG1 (hE60), were obtained from M. Diamond,
and hE60-N297Q was obtained from S. Johnson (MacroGenics,
Inc.). The mouse E60 IgG2a mAb was originally generated against
WNV E protein, reacts with an epitope in the fusion peptide in
domain II, and cross-reacts with DV E proteins [25]. The
generation of a chimeric human-mouse E60 with the human IgG1
constant regions and the mouse VH and VL was performed as
described previously [26]. Point mutations in the Fc region that
abolish FccR and C1q binding (N297Q) or C1q binding alone
(A330L) were introduced by QuikChange mutagenesis (Strata-
gene). All recombinant antibodies were produced after transfection
of HEK-293T cells, harvesting of supernatant, and purification by
protein A affinity chromatography.
Infection of AG129 mice
AG129 mice [54] were originally obtained from M. Aguet
(Swiss Institute for Experimental Cancer Research, Epalinges,
Switzerland) and were bred in the University of California (UC)
Berkeley Animal Facility. All experimental procedures were pre-
approved and were performed according to the guidelines of the
UC Berkeley Animal Care and Use Committee.
Generation of mouse anti-DV sera. Six to eight week-old
AG129 mice were infected subcutaneously with 10
5 pfu of either
DV1 strain 98J or DV2 strain PL046 or PBS. Mice were sacrificed
by terminal bleed six to eight weeks after infection. Serum was
separated from whole blood by centrifugation, heat-inactivated,
and frozen at 280uC.
Enhancement of DENV in vivo. Mice were injected
intraperitoneally with mAb, PBS, or anti-DV sera in a total
volume of 400 ml, then infected 20–24 hours later with DV by iv
injection into the tail vein in a total volume of 100 ml. In some
experiments, 50–100 ml of blood was obtained via retro-orbital
bleed approximately 18 hours post-transfer (i.e., 4–6 hours prior
to DV infection) and processed into serum as above.
Measurement of cytokines and platelet counts
Cytokines were measured using commercially available ELISA
kits (EBioscience). Platelet counts were obtained by diluting 20 ml
of anticoagulated blood into Unopette reservoirs (BD) and
counting on a hemocytometer.
Quantitation of virus in tissues by plaque assay
Viral load was determined in the indicated tissues as previously
described [52], and expressed as either pfu/g (all solid tissues) or
pfu/10
9 cells (bone marrow and PBMCs). To obtain PBMCs,
200–300 ml of whole blood was collected into EDTA-coated
microtainer tubes (Becton Dickinson) after cardiac puncture.
Samples were washed 3 times in red blood cell lysis buffer
(eBioscience) and once in cold PBS, and resuspended in 250 ml
alpha-MEM with 5% fetal bovine serum (FBS, Hyclone), 10 mM
Hepes (Invitrogen) and 100 U penicillin/100 mg streptomycin (P/
S; Invitrogen).
Quantitation of virus in serum by quantitative RT-PCR
Viral RNA was extracted from 60 ml serum aliquots using Qia-
Amp Viral RNA recovery kit (Qiagen). Quantitation of viral RNA
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Biosystems, Foster City, CA) and an ABI PRISM 7700 sequence
detection system as described [55]. Viremia is expressed as plaque-
forming unit equivalents/ml, which was calculated by dividing the
genomic RNA copy number in each sample by the genome:pfu
ratio of C6/36-derived virus as determined by plaque assay and
qRT-PCR.
Immunohistochemistry
Tissues were collected at day 3.5 (n=3–6 mice per group),
formalin-fixed, and processed into paraffin sections. Serial sections
from each tissue were stained for NS3 using MAb E1D8 or an
isotype control as previously described [12]. For quantification of
NS3
+ cells, at least ten visual fields were counted for each sample
except bone marrow, where four fields from four independent
sections were counted due to the small area of mouse bone cross-
sections. All pairwise comparisons were performed by two-sided
Wilcoxon Rank Sum tests.
Flow cytometry
Bone marrow aspirates were collected by perfusing two
femurs with cold, complete RPMI media (Invitrogen) containing
10% FBS (Hyclone), 10 mM Hepes (Invitrogen) and 100 U
penicillin/100 mg streptomycin (P/S; Invitrogen). Resuspended
cells were washed once in red cell lysis buffer and once in D-PBS
(Invitrogen). The cells were subsequently resuspended in flow
cytometry buffer containing D-PBS, 2.0% bovine serum albumin
(BSA; Fisher Scientific) and 0.02% sodium azide (Sigma-Aldrich)
and plated in a 96-well U-bottom plate (Becton-Dickinson) at
1610
6 cells/well. Cells were blocked with 5% normal rat serum
(Jackson Laboratories) diluted in flow cytometry buffer. Bone
marrow cells were stained extracellularly using CD11b-PeCy7
(eBioscience), CD11c-PE (eBioscience), and F4/80-TC (Caltag) or
isotype control, and then fixed in 2% paraformaldehyde (Ted
Pella, Inc.), washed and permeabilized with 0.1% saponin (Sigma-
Aldrich). Intracellular staining was then performed with either 1)
human anti-DV E mAb 87.1 (F. Sallusto and A. Lanzavecchia,
Institute for Research in Biomedicine, Bellinzona, Switzerland) or
isotype control mAb hIgG1 WNV-E16 (M.S. Diamond) followed
by secondary goat anti-human IgG conjugated to Alexa488
(Invitrogen) or 2) mouse anti-NS3 mAb E1D8 conjugated to
Alexa488 (Invitrogen) or isotype control (mIgG2a-Alexa488
(Invitrogen)). Livers were harvested into 10 mL cold, complete
RPMI media and subsequently digested using 20 mg/mL
collagenase VII (Sigma-Aldrich), washed, and the digested tissue
passed over a 70-mM cell strainer (Fisher). The resulting cells were
centrifuged over an Optiprep gradient (14.7%/22.2%), washed
once with D-PBS, and plated in a 96-well plate at 1610
6 cells/
well. The cells were stained extracellularly using CD31-PE
(eBioscience), fixed in 2% PFA, permeabilized with 0.1% saponin,
and stained intracellularly with either anti-E or anti-NS3 mAbs or
isotype control as above. Data was collected using either an LSR II
or FC-500 flow cytometer (Becton-Dickinson) and analyzed using
FlowJo v8.8.6 software (TreeStar).
Surface plasmon resonance
Monoclonal antibodies at a concentration range of 12.5 to
200 nM were injected over the surface of a Biacore 3000
instrument with immobilized E protein (,300 RU) at a flow rate
of 30 ml/min for 120 seconds and a dissociation time of 180
seconds. Binding curves at concentration zero were subtracted as
blank. Kinetic parameters were calculated by fitting binding
curves to a bivalent analyte binding model. The kinetic parameters
were similar for binding of both mAb variants to E protein, as the
difference between affinities is less than two-fold.
Preparation of F(ab)92 fragments and ELISA
4G2 F(ab)92 fragments were generated using the F(ab)92
Preparation kit (Pierce) according to the manufacturer’s instruc-
tions. To ensure that the F(ab)92 fragments did not contain
residual Fc portions, the 4G2 F(ab)92 proteins were diluted in
SDS-PAGE loading dye, boiled, and electrophoresed on a 10–
20% Tris-glycine gel (Bio Rad) and stained with Colloidal Blue
(Invitrogen) overnight. To measure the stability of F(ab)92
fragments in vivo, sera from mice given different amounts of
F(ab)92 were tested by ELISA for DV2 E protein binding. In brief,
ELISA plates (Fisher Scientific) were coated with 2 mg/ml of
recombinant DV2 E protein (Hawaii Biotech Inc.) in carbonate
coating buffer, pH 9.6 overnight at 4uC. The plate was blocked for
1 hour at room temperature in 5% nonfat dry milk and 5%
donkey serum (Jackson Laboratories) in PBS-0.5% Tween 20.
After washing, 50 ml of serum containing intact 4G2 or F(ab)92
4G2 diluted 1:10 in blocking buffer was added to the plates. After
washing, 100 ml of either goat anti-mouse anti-F(ab)92 (Jackson
Laboratories) or goat anti-mouse anti-Fc (Jackson Laboratories)
diluted 1:1000 in PBS-T was added as secondary antibody.
Biotinylated mouse anti-goat antibody (Jackson Laboratories) was
added as a tertiary antibody, followed by streptavidin-alkaline
phosphatase (Zymed). P-Nitrophenyl phosphate (PnPP; Sigma
Aldrich) was added as the substrate, and the reaction was stopped
with 3M NaOH and read in an ELX-808 ultra microplate reader
(Bio-Tek Instruments) at 405 nm.
Neutralization assay using U937 DC-SIGN cells and
plaque reduction neutralization test
Serial 3-fold dilutions of antibodies were mixed with DV2
D2S10 virus at a multiplicity of infection (MOI) generating 7–15%
infection of U937 DC-SIGN cells in a 96-well U bottom plate as
described previously [14]. After infection for 24 hours, the cells
were washed once with flow cytometry buffer and fixed in 2% PFA
for 10 minutes at room temperature. The cells were then
permeabilized in FACS buffer with 0.1% saponin (Sigma Aldrich)
and stained with 2.5 mg/mL 4G2-Alexa 488 (Invitrogen). The cells
were washed twice, and percent infection determined by flow
cytometry on a Beckman Coulter EPICS XL flow cytometer. The
resulting raw data was expressed in GraphPad Prism 5.0 software
as percent infection versus log10 of the serum dilution, and a
sigmoidal dose-response curve with a variable slope was applied to
determine the antibody titer coinciding with a 50% reduction in
infection as compared to the no-serum control (NT50). The plaque
reduction neutralization test (PRNT) was performed in duplicate
as described previously [13].
In vitro measurement of ADE
Serial 3-fold dilutions of antibody were mixed with DV2 D2S10
virus in duplicate for 45 min at 37uC, then mixed with K562 cells
at MOI of 1 for 48 hours [23] in a 96-well plate. The cells were
subsequently washed once with FACS buffer and fixed in 2% PFA
for 10 minutes at room temperature. To stain, the cells were
permeabilized in FACS buffer with 0.1% saponin (Sigma Aldrich),
and then stained with 2.5 mg/mL 4G2-Alexa 488 (Invitrogen).
The cells were washed twice, and percent infection was
determined by flow cytometry on a Beckman Coulter EPICS
XL flow cytometer. The resulting data was expressed as percent
cellular infection versus log10 of the serum dilution in Microsoft
Windows Excel.
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Kaplan-Meier survival curves were used to display mortality
data, and log rank analyses were used to determine statistical
significance between experimental groups. Non-parametric anal-
yses using the two-sided Wilcoxon rank sum tests were used for
pairwise comparisons of viral load, cytokines, and platelet counts.
A Fisher’s exact test was used to examine survival on day 4 post-
infection in F(ab9)2 experiments because the instability of F(ab9)2
fragments necessitated comparison at a single time point.
Calculations were performed in GraphPad Prism 5.0 software.
Supporting Information
Table S1 Effect of anti-DV1 serum and viral dose on morbidity
and mortality
Found at: doi:10.1371/journal.ppat.1000790.s001 (0.05 MB PDF)
Table S2 Morbidity and mortality with 10
5 pfu DV2 inocula-
tion under varying antibody conditions
Found at: doi:10.1371/journal.ppat.1000790.s002 (0.06 MB PDF)
Figure S1 Phenotyping of DV-infected cell types in bone
marrow and liver under non-ADE and ADE conditions. Mice
were administered naı ¨ve serum (NMS) and 24 hours later injected
iv with either PBS (uninfected) or 10
5 DV2 D2S10 (non-ADE) or
were infected with 10
5 DV2 D2S10 24 hours after receiving anti-
DV1 serum (ADE). Bone marrow aspirates and livers were
collected on day 3.5 post-infection. (A) The bone marrow cells
were stained and collected as described in Materials and Methods.
The majority of DV
+ cells were CD11b
+ (65%); thus, cells were
initially gated on CD11b (monocyte marker). The isotype control
for CD11b is depicted in pink in the initial histogram. Scatterplots
of CD11b
+ cells stained with anti-DV E or isotype control and
either CD11c (dendritic cell marker) or F4/80 (macrophage
marker) are shown for one representative animal out of six. Similar
results were obtained using anti-DV NS3 mAb E1D8: of CD11b
+
cells, 0.33%, 0.96% and 3.03% were CD11c
+NS3
+ in uninfected,
non-ADE, and ADE conditions, respectively; and 0.39%, 0.96%,
and 3.34% were F4/80
+NS3
+ in uninfected, non-ADE, and ADE
conditions, respectively. (B) Livers were processed and stained as
described in Materials and Methods. Data collection and analysis
was performed as in (A). Scatterplots of cells stained with CD31
(endothelial cell marker) and anti-DV NS3 or isotype control are
shown for one representative animal out of six. Similar results were
obtained with human anti-DV E.
Found at: doi:10.1371/journal.ppat.1000790.s003 (1.45 MB TIF)
Figure S2 Characterization of F(ab9)2 fragments of 4G2. MAb
4G2 was processed into F(ab9)2 fragments using the Immunopure
F(ab9)2 kit (Pierce). (A) Intact 4G2 and purified F(ab9)2 fragments
were tested for reactivity against purified DV2 E protein (Hawaii
Biotech Inc.) by ELISA and detected with anti-F(ab9)2-specific
antibody. (B) ELISA was performed as in (A), but with detection
antibody specific for the Fc portion of mouse IgG. (C) Mice were
administered 4G2 ip at doses shown to enhance infection in vivo (5
or 80 mg), and serum was collected 24 hours later. 4G2 F(ab9)2
fragments were administered to mice iv and serum collected 1 and
24 hours later. Serum levels of intact 4G2 and F(ab9)2 fragment
were measured by reactivity to DV2 E protein by ELISA using
anti-F(ab9)2-specific antibody.
Found at: doi:10.1371/journal.ppat.1000790.s004 (0.37 MB PDF)
Figure S3 Further characterizations of E60 antibody variants.
(A) Monoclonal antibodies at a concentration range of 12.5–
200 nM were injected over the surface of a Biacore 3000 with
immobilized E protein (,300RU) at a flow rate of 30 ml/min for
120 sec and a dissociation time of 180 sec. Binding curves at
concentration zero were subtracted as blank. Kinetic parameters
were calculated by fitting binding curves to a bivalent analyte
binding model. The kinetic parameters are similar for binding of
both mAb variants to E protein, as the difference between affinities
is less than two-fold. (B) Neutralizing activity of E60 variants on
DC-SIGN-expressing U937 cells. DV2 was incubated with the
indicated concentrations of each E60 variant MAb, applied to
U937 cells expressing the DV attachment receptor DC-SIGN, and
the percentage of cells infected with DV was assessed 24 hours
later by flow cytometry staining with Alexa488-labelled anti-DV E
protein MAb. (C) E60 A330L enhances DV infection in vitro.
Enhancement assays were performed as in Figure 6A using E60-
A330L. E60-N297Q is shown for comparison. D. E60 A330L
enhances DV infection in vivo. Mice were administered 20 mg E60-
A330L or PBS (no MAb) ip, then infected 24 hours later with
10
6 pfu DV2 iv. Survival was monitored for 10 days. n=4 for
E60-A330L recipients and n=6 for no MAb controls; p=0.014
by logrank test.
Found at: doi:10.1371/journal.ppat.1000790.s005 (0.68 MB PDF)
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